About Us

Marizymeh&M2
Marizymeh&M5
Marizymeh&M4
Marizymeh&M3
A Global Company Focused On Unparalleled Healthcare Solutions

On a mission to address the urgent need for higher mortality

Marizyme is committed to the development, acquisition, and commercialization of healthcare products, devices & therapies for our B2B and B2C clients across the world. Our dedication to research with a purpose is built on our scientific and medical skills, as well as a distinct patient-inspired emphasis.

A Global Company Focused On Unparalleled Healthcare Solutions

Marizyme is committed to the development, acquisition, and commercialization of healthcare products, devices & therapies for our B2B and B2C clients across the world. Our dedication to research with a purpose is built on our scientific and medical skills, as well as a distinct patient-inspired emphasis.

Robust Product Pipeline

Our robust pipeline of product candidates reflects our expertise in developing products for unmet clinical needs - an area in which we have a track record of success. Owing to more than a decade of expertise, we are able to reduce clinical development time and substantially increase the probability of late-stage product success

Marizyme(M&H)
Marizyme Quality

Smart Technology for Big Differences

90% of people who have Chronic Kidney Diseases (CKD), don’t even know they have it. The unknown can sometimes be worse than knowing. That’s why at Marizyme, we use our multi-technology platform to take care of unmet clinic needs.

Evaluate and develop our systems on a regular basis to ensure the highest quality medical products, devices & therapies
Maintain policies and processes in all countries where our product is sold to guarantee regulatory compliance
Maintain the same high standards with our suppliers, partners, and contractors as we do with ourselves

EXECUTIVE MANAGEMENT

maryzme photo(David)
Chief Executive Officer & Director
David
Barthel

Mr. David L. Barthel is an experienced executive leader in the healthcare and medical device space with the proven ability to straddle the worlds of large corporations and early stage businesses. Has relevant P&L and senior leadership experience

Read more/lessas a Managing Director for Henry Schein’s Orthopedic Surgical Instrumentation business, as an Area Vice President for the Southeast Division for Medtronic GIH in Atlanta, GA and as Vice President, SmartPill for Given Imaging in Duluth, GA. Previously as President and CEO, led The SmartPill Corp., a GI medical device start-up in Buffalo, NY from a patent for an ingestible motility capsule through product development, fund raising, clinical trials, FDA approvals, manufacturing, reimbursement, commercialization and eventual sale of the business.
David has coordinated and executed multiple capital fundraising efforts, driving significant revenue growth and has the ability to establish commercial viability across multiple disciplines, strategic partners and sales channels. David’s focus has been on building businesses through strategic partnerships, global market and channel development, talent and cross functional team development and the creation of economic and clinical value propositions that drive sustainable growth.
Has earned a Bachelor of Arts Degree from St. Norbert College in Depere, Wi and an MBA from Lake Forest Graduate School of Management in Lake Forest, Il.

maryzme photo(Y)
Chief Financial Officer
George Kovalyov

George was most recently Vice President Finance at Phivida Holdings Inc (VIDA: CSE), a publicly traded company that has raised over $19 million since its IPO in December 2017. He has spent 11 years as an experienced financial controller

Read more/lessworking on public companies audits and financial statements to GAAP and IFRS.
George received his Chartered Accountant designation through the Institute of Chartered Accountants of British Columbia and Bachelor of Business Administration, Diploma in Accounting – Kwantlen University.
Mr. Kovalyov is also Founder and President of GVK Group Chartered Accountant. He has over 15 years experience as CPA, financial controller for both private and public companies, served as Vice President Finance at Phivida Holdings Inc (VIDA: CSE) merged with larger (CHOOM:CSE). He has Over $20 million in capital raising and capital management experience and is the Founder of GVK Group, sold to MCA Chartered Accountants.

maryzme photo(A)
Executive Vice President, Chief Scientific Officer
Catherine J. Pachuk, Ph.D.

Dr. Pachuk has more than 25 years of research and development leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device and vaccine development with significant experience in nucleic acid

Read more/less

based therapeutic platforms including ASO, RNAi and nucleic acid-based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, metabolic disease, HCC and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in medical devices and pharmaceuticals.

Following a post-doctoral fellowship at SmithKline Beecham, she joined Apollon, Inc. to develop programs in oligonucleotide-based therapeutics, and subsequently DNA-based vaccines for both viral and oncology indications. Following the acquisition of Apollon, Inc. by Wyeth-Ayerst Research in 1998 she continued to direct several vaccine programs, which resulted in several plasmid-based vaccine products being advanced into clinical trials. During this time, Dr. Pachuk worked with FDA’S CBER division in the drafting of a “Points to Consider” document regarding considerations for administration of plasmid DNA compounds in humans. In 2001, she co-founded Nucleonics, a biotech focused on the development of RNAi-based therapeutics, one of which was advanced into clinical studies in Chronic Hepatitis B patients. Until April 2008, she was VP of Preclinical Research. Dr. Pachuk then went on to lead biology and preclinical development efforts for Pfizer’s oligonucleotide therapeutic programs (ASO and siRNA) in the areas of oncology and metabolic disease and was a member of the Executive Leadership Team. Dr. Pachuk also has significant experience in nucleic-acid delivery and has led nucleic acid-delivery and formulation development programs for ASO, plasmid-based therapeutics, and siRNA at Apollon/Wyeth Vaccines, Nucleonics and Pfizer. Dr. Pachuk also was responsible for obtaining more than $1.8 million in government and private grants.

Dr. Pachuk is currently a Scientific Advisory Board member for Ocugen, Inc. where she advises on the development of a COVID-19 vaccine and is currently an invited expert curator for the American Society of Microbiology’s COVID-19 research registry. She is also an adjunct faculty member at both Florida Atlantic University and Baruch Blumberg Institute.

maryzme photo(Z)
Chief Medical Officer
Steven Brooks, MD, MBA, FACC

Dr. Steven S. Brooks currently serves as Chief Medical officer for Marizyme, Inc. He is a multi-faceted health care consultant, publisher, and clinical trialist with experience including regulatory strategy, scientific and medical due diligence

Read more/less and medical technology commercialization. Previously, Steve was an Interventional Cardiologist and Assistant Professor at the University of Maryland Medical Center and then worked in private practice. Beginning in 2007 Steve worked for six years as a Medical Officer for the Food and Drug Administration in the Division of Cardiovascular Devices in the Peripheral Interventional Devices Branch and Interventional Cardiology Devices Branches. In this role he performed medical device review of cardiovascular and vascular surgery related products throughout the full product lifecycle. After FDA Steve worked as a consultant for multiple firms and independently, and as an embedded employee in several medical technology companies. Steve earned an MBA from the Johns Hopkins Carey School of Business in the Business of Medicine Program.

maryzme photo(B)
Chief Medical Officer, My Health Logic
Claudio Rigatto, M.D

Dr. Claudio Rigatto is a Kidney Disease specialist and Associate Professor of Medicine at the University of Manitoba, as well as the Academic Director of the Chronic Disease Innovation Centre. As a clinician

Read more/less

Dr. Rigatto deeply engaged in the care of patients with CKD or on dialysis, with a focus on home treatments of kidney disease. As a researcher, Dr. Rigatto has deep expertise in biomarkers, risk prediction, and virtual care methods. His research program is focused on developing and implementing technologies to help patients self-manage complex health conditions at home.

He has developed POC tests (with Dr Lin) for early detection and risk prediction in CKD, as well as tablet based tools to monitor patient health status at home (telemonitoring). He has published over 180 peer-reviewed articles, and has presented at numerous national and international meetings.

In addition to his clinical and academic work, he currently serves as President-Elect of the Canadian Society of Nephrology, Associate Editor for the Canadian Journal of Kidney Health and Disease, and as investigator and subcommittee co-chair of the Can-SOLVE-CKD network of patient oriented research programs. He received his medical training at the University of Manitoba, including a BSc. in Medicine and at Memorial University in Newfoundland where he received his MSc. in Medicine.

maryzme photo(Ross)
Vice President of Finance
Harrison Ross, CFA

Harrison brings experience in both public and private capitals markets, enhanced by a strong background in financial reporting. Mr. Ross specializes in equity research and valuation, and has experience in areas of portfolio strategy and asset allocation.

Read more/less

He was CFO at DC Acquisition, a Capital Pool Company listed on the TSX.V that raised over $2.5 million and successfully completed its qualifying transaction.

He had helped manage over $500 million at Duncan Ross and Associates and was an analyst at Belkorp Industries.

Harrison received his Bachelor of Management and Organizational Studies degree from University of Western Ontario, with specialization in Accounting. Harrison is a CFA Charterholder.

maryzme photo(Amar)
Director of Business Development
Amar
Dhaduk

Amar Dhaduk was named Director of Business Development at Marizyme in 2021. He has had previous roles in other companies where he served as President and Vice President leading efforts for commercializing and marketing medical devices for 7 years.

Read more/less

His responsibilities included medical device marketing, project management, customer /distributor relationship management, and business development.

maryzme photo(Navdeep)
Director of Quality Affairs & Regulatory & management representative
Navdeep Cheema

Navdeep holds 12 years of experience in Quality Management Systems in pharmaceuticals and medical devices. She entered into the world of Quality Assurance after finishing Master of Science in Biotechnology. Her first exposure to QMS started with understanding of how important it is to follow the quality process as the devices and drugs manufactured by the company touch lives of thousands of people. Navdeep is committed to the responsibility to provide patients with safe and effective solutions. Her extensive passion and experience led her the opportunity to build an entire Quality Management System for a start up company. She is also a certified lead auditor and a Green Belt Lean Six Sigma.

BOARD OF DIRECTORS

maryzme photo(Dhaduk)
Chairman of the Board
Dr. Vithalbhai D. Dhaduk

Dr. Dhaduk has more than 30 years’ professional experience as neurologist who has served as Head of Neurology at Professional Neurological Associates for 20 years and Assistant Professor of Neurology at Commonwealth Medical College.

Read more/less

Dr. Dhaduk currently serves as President and Chairman at Professional Neurological Associates (since 1987), Chairman of Dap Dhaduk 1 to 8 (since 1998), Chairman of Caritas International Trading Inc. (since 2011), President and Chairman of Caritas Real Estate Group (since 2011), President and Chairman of Core Hospitality LLC (since 2011), President and Chairman of Star Real Estate LC (since 2012), President and Chairman of Coracias Advanced Technology LLC (since 2016), as a Director on the Board of Directors at FNCB Bancorp, Inc. (NASDAQ: FNCB, since 2017), Board of Directors for The Wright Center (since 2017), and President and Chairman of CorePharma, LLC (since 2018). Previously, Dr. Dhaduk had served as Chairman of Global Pharma Analytics (2012 – 2019), as President and Chairman of Somahlution, LLC (2012 – 2019), President and Chairman of Apicore LLC (2005 – 2016), President and Chairman of R&D Future Aire Tech (2011 – 2013), President and Chairman of Neuron Biotech (2007 – 2013, and President and Chairman of Synerx Pharmaceutical (2007 – 2013). Dr. Dhaduk is a managing trustee of charitable trust and past President and Chairman of Saurashtra Patel Cultural Samaj.

Dr. Dhaduk received a Bachelor of Medicine and Bachelor of Surgery in 1980 from M.P. Shah Medical College in Jamngar, India. Dr. Dhaduk has a Pennsylvania and New Jersey medical license (both since 1985), PGY-1 waiver on basis of excellence in post-graduation from the Board of Psychiatry and Neurology (1984), FLEX (Federal Licensing Examination (1984) and ECFMG Certification (1981). Dr. Dhaduk has received the following awards: David Dunn Memorial Award for Outstanding Teaching and Study of Neurology, Medical College of Pennsylvania (1986 – 1987) and Honors in Medicine, M.P. Shah Medical College, India (1980). Dr. Dhaduk has memberships in Fellow of the American Academy of Neurology, Pennsylvania Medical Society, Lackawanna County Medical Society, American Medical Association, MS Society, Parkinson’s Support Group, National Headache Foundation, Alzheimer’s Support Group and Who’s Who Registry.

Dr. Dhaduk has published in the Journal of Neurology, Neurosurgery, and Psychiatry the following: Partial Ataxic Hemiparesis (1988) and Polyneuritis Cranialis in Lyme Disease (1987). He has presented at the following: CT Scan, EEG, and Brain Mapping in Acute Stroke at American Academy of Neurology (April 1987) and Magnetic Resonance Imaging of Intracranial Vascular Malformations at American Society of Neuroimaging (February 1986).

maryzme photo(Terry)
Independent Director
Terry Brostowin, Esq.

Mr. Brostowin was appointed as an independent director on December 14, 2018. Mr. Brostowin is an accomplished attorney admitted to the Federal Courts in both the Eastern and Southern Districts of New York and the District of New Jersey.

Read more/less

He has extensive expertise in contracts and commercial litigation. Mr. Brostowin has provided his opinion to the New York City Mayor’s office of judicial screening committees on judicial reappointments and was a compliance specialist ensuring the Department of Correction’s compliance with various Federal Court ordered mandates and ensured the financial integrity of various vendors doing business with the Financial Systems Division. Mr. Brostowin has been affiliated with the law firm Brostowin & Associates, PC, since 2009. From 2002 to 2009, Mr. Brostowin was affiliated with the law firm Conway & Brostowin, LLC.

maryzme photo(X)
Independent Director
Julie
Kampf

Julie Kampf is a global business executive and thought leader on talent and diversity, with 30 years of experience in the life science and retail/consumer fashion industries and on not-for-profit Boards of Directors.

Read more/less

She is currently CEO of JBK Associates International, which she founded in 2003, and has grown to become a multi-million-dollar company as one of INC’s fastest growing private companies, four consecutive years, beginning in 2011. Julie has a reputation for delivering results that exceed expectations working with life science company CEOs and boards, ranging from companies included in the Fortune 100 to startup companies.

Prior to founding JBK and moving into the life science industry, Julie gained deep business knowledge in product development, marketing, sales, and organizational development, having started her 17-year career in the fashion industry as a Macy’s Executive Trainee with a subsequent series of roles of increasing responsibility at Warnaco Inc., Hartmann Inc and Michael Stevens, LTD, ultimately rising to Sr. VP with P&L responsibilities with a track record of consistently growing revenues and delivering strong profits.

Julie has significant not-for-profit board and advisory committee experience having served on Howard University’s School of Communications Board of Visitors, where she helped launch an entrepreneurial incubator and established an award for student entrepreneurs. Her not-for-profit board service spans the Linkage Diversity Summit, Enterprising Women magazine, International Association of Corporate and Professional Recruitment, Girl Scout Council of Bergen County, Guiding Eyes for the Blind. Additionally, she has served on the Executive Committee of Good Grief, a national leader in delivering grief services to children and their families.

Julie has received numerous awards, including having been recognized as one of New Jersey’s Best 50 Women in Business, an Enterprising Woman of The Year, an Ernst & Young Entrepreneurial Winning Woman and a Brava Smart CEO Winner. In 2013 and 2009, Julie was recognized as one of the PharmaVoice 100 Most inspiring people in the Life Science Industry.
Julie earned a B.A. in Political Science from the University of Rhode Island, where she minored in Marketing.

maryzme photo(William)
Independent Director
William Hearl, Ph.D.

Dr. Hearl is the founder of Immunomic Therapeutics, Inc. and is an experienced and successful life science businessman and entrepreneur. Dr. Hearl is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities.

Read more/less

The advent of the commercial development of LAMP technology came from discussions between Dr. Hearl and Dr. Tom August at Johns Hopkins University. Based on their mutual vision of the value of LAMP, ITI emerged and began operations in 2006. Dr. Hearl’s extensive experience in intellectual property management and business development led to the reward of a sub-license of the LAMP technology to Geron Corporation within 30 days of initiating operations and subsequent license agreements, valued at more than $300 million, in 2015 with Japan-based Astellas for next generation allergy vaccines based on the LAMP platform.

Dr. Hearl is also a founder of Capital Genomix, Inc. (CGI), a Maryland-based biomarker and drug discovery company and served as its first chief executive officer from inception in 2000 to late 2002 when he assumed the role of chief scientific officer. Dr. Hearl raised seed funds and Series A & B funding for CGI (approximately $5 million in cash/debt). He also acquired the Dynex Technologies division of Thermo Scientific in a leveraged acquisition deal. Dynex was subsequently divested and yielded a remarkable tenfold return to the company.

Dr. Hearl is also responsible for the acquisition and development of the core technologies of Capital Genomix: GeneSystem320™ was licensed exclusively from MD Anderson Cancer Center and the ImmunoMouse™ was invented by Dr. Hearl. Dr. Hearl also has an established record of scientific productivity over his 20 years of work in the biotech industry. He started his career as a bench scientist at Electro-Nucleonics, Inc. and developed blood-based diagnostics for HIV, HTLV-I and Hepatitis C. He later worked at Life Technologies and directed the immunodetection group. Under Dr. Hearl’s direction, the lab developed several innovative antibody-based detection kits and reagents. He moved into scientific management when he became the director of research and development at Kirkegaard & Perry Laboratories, Inc. in 1994.

Dr. Hearl earned his Ph.D. in biochemistry from the University of Tennessee and B.S. from East Tennessee State University.